医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Tianjin SinoBiotech Ltd. & Beijing Bio-Fortune Ltd. Announce a US Market Licensing Agreement for Their Intellectual Property on the Treatment of Neutropenia With One of the Global Top 10 Pharmaceutical Companies

2013年06月11日 PM09:25
このエントリーをはてなブックマークに追加


 

BEIJING

Prof. Zailin Yu, Yan Fu with Tianjin SinoBiotech Ltd. & Beijing Bio-Fortune Ltd. (the “Licensor”), privately held biotechnology and biopharmaceutical companies, announced today that they have entered into a US market patent license agreement with one of the global top 10 pharmaceutical companies (the “Licensee”) on their intellectual property of the novel recombinant human serum albumin fusion protein drug for treatment of human neutropenia.

Under the terms of the agreement, the Licensee will be provided a license to develop and commercialize potential drug products for the treatment of neutropenia for the US market. The Licensor will continue to develop and commercialize its own proprietary novel recombinant fusion protein drug for treatment of human neutropenia which is currently in clinical Phase I/II studies with tumor and cancer patients in China.

“We are delighted to enter into this patent license agreement with a world-class pharmaceutical operator for the novel protein drug for the US market,” said Professor Zailin Yu, Chairman of Tianjin SinoBiotech Ltd. & CEO of Beijing Bio-Fortune Ltd. “We believe that this novel protein drug treatment is very promising and we will continue to pursue clinical trials for the China market. This license agreement highlights the broad potential of our R&D capabilities and further supports the Licensor’s strategy to maximize our proprietary protein based platforms for successful therapeutics drugs.”

About Tianjin SinoBiotech Ltd., Beijing Bio-Fortune Ltd. & FortuneRock (China) Ltd.

Tianjin SinoBiotech Ltd. & Beijing Bio-Fortune Ltd. are wholly owned companies of FortuneRock (China) Ltd., a privately held biotechnology and biopharmaceutical company. FortuneRock and its subsidiary companies are focused on the discovery, development, and commercialization of novel, patent-protected gene-based recombinant protein drugs with high clinical value for the treatment of life-threatening and debilitating diseases, including cancer, inflammation, autoimmune and infectious diseases.

FortuneRock has unique novel fusion protein technology platforms with over 16 patents in USA (4 granted, 3 pending), China (7 granted, 1 pending) or PCT (1 pending) and all of which have been published. The Long Acting Recombinant Protein Drug Platform can be used for developing many therapeutic protein drugs with longer half life or long acting functions including the restructuring of the well known recombinant protein drugs, such as GCSF, Interferon(s), EPO, HGH, Interleukins, and skin cell growth factors, etc. Along with the High Efficacy Yeast Expression System Platform, FortuneRock can produce mass quantities of high quality recombinant protein products. FortuneRock with its subsidiary companies has extensive experience in recombinant protein drug development and conducting pre-clinical, clinical trials in China for itself and its partners.

In addition, FortuneRock also has a joint-venture company set up in 2003 with Peking University’s PKU Bioway Group Ltd. The JV, Beijing Bioway-Fortune Research Center for Gene Drugs Ltd., is the first research center for gene drugs in China.

For more information please visit its website at http://www.tsbsino.com.

CONTACT

FortuneRock (China) Ltd.
Prof. Zailin YU, Chairman & CEO
Tel: +86-10-6276-0812
Fax:
+86-10-6276-0812
Email: zyu88@yahoo.com;
zyu@fortunerock.com
www.tsbsino.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent